Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 93

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 93
---
 expect to receive approximately
$ million in net proceeds from the sale of Ordinary Shares offered by us in this offering (approximately
$ million if the Representative’s exercises its over-allotment option in full), based upon an
assumed public offering price of $ per Ordinary Share, which is the midpoint of the price range set forth
on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable
by us.

Each $0.25 increase or decrease
in the assumed initial public offering price of $ per Ordinary Share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $ million,
assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Ordinary
Shares we are offering. An increase (decrease) of in the number of Ordinary Shares offered by
us would increase (decrease) the net proceeds to us from this offering by $ million, assuming no change
in the assumed initial public offering price and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $     million for development activities and preparation of the PMA submission for GelrinC; |

| ● | approximately $      million to complete the pivotal trial for GelrinC and related activities; and |

| ● | the remainder for working capital and general corporate purposes and possible future acquisitions. |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is necessary.
Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate with certainty
the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone basis. Amounts
and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization efforts,
regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will